Menu

Osteoporosis in Children with Prader-Willi Syndrome

Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. Its severity is dependent on both bone mineral content and bone quality. Bone mineral, which accounts for about two-thirds of total bone strength, is commonly used to define osteoporosis. In the general population, bone mineral density, or amount of bone mineral per unit of bone mass, is relatively low in early life and gradually increases throughout childhood and adolescence, peaking during the third decade of life. Thereafter, progressive bone mineral loss occurs. Bone mineral density during childhood and adolescence is dependent on several factors including hormones (growth hormone, gonadal steroids, vitamin D), nutrition (particularly calcium), and neuromuscular stimulation (exercise). Deficiencies in any of these areas can lead to inadequate bone density and osteoporosis.
Significantly decreased total bone and spine mineral density and total bone mineral content are reported in PWS subjects but with no significant evidence of bone loss compared with controls suggesting a possible lack of bone mineral deposition during growth (e.g., adolescence). These changes may be due to low calcium and vitamin D intake with calorie-restricted diets and in the latter case, lack of sun exposure. Calcium and vitamin D supplements may be required. A program of physical activity may help prevent the development of osteoporosis by providing neuromuscular stimulation necessary for bone mineral deposition.
Decreased production of sex or growth hormones in individuals with PWS may also play a role. Growth hormone therapy, which is recommended for use in children with PWS, is associated with more normal bone mineral density. Gonadal steroid therapy may also help prevent osteoporosis. [Lee: 2000] [Allen: 2004]

Resources

Information & Support

For Professionals

Genetics in Primary Care Institute (AAP)
The goal of this site is to increase collaboration in the care of children with known or suspected genetic disorders. Includes health supervision guidelines and other useful resources; a collaboration among the Health Resources & Services Administration, the Maternal and Child Health Bureau, and the American Academy of Pediatrics.

Authors

Author: Merlin G. Butler, MD, PhD - 9/2008
Reviewing Authors: Judy L. Welch, RN, BSN - 9/2008
Kyna Byerly, MS, CGC - 8/2008
Content Last Updated: 1/2011

Funding/Support

This page was developed in partnership with the Heartland Genetic Services Collaborative and was funded in part by a Health Resources Services Administration (HRSA) cooperative agreement (U22MC03962). We appreciate the Prader-Willi Syndrome Association (USA) for their outstanding support of individuals with PWS and their families and for the information they provide on their website – www.pwsausa.org – to which we have provided several links within the Diagnosis Module.

Page Bibliography

Allen DB, Carrel AL.
Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
J Pediatr Endocrinol Metab. 2004;17 Suppl 4:1297-306. PubMed abstract

Lee PD.
Effects of growth hormone treatment in children with Prader-Willi syndrome.
Growth Horm IGF Res. 2000;10 Suppl B:S75-9. PubMed abstract